Cargando…

Effect of Colchicine in reducing MMP-9, NOX2, and TGF- β1 after myocardial infarction

BACKGROUND: According to WHO 2020, CAD is the second leading cause of death in Indonesia with death cases reaching 259,297 or 15.33% of total deaths. Unfortunately, most of the patients of CAD in Indonesia did not match the golden period or decline to be treated with Percutaneous Coronary Interventi...

Descripción completa

Detalles Bibliográficos
Autores principales: Suryono, Suryono, Rohman, Mohammad Saifur, Widjajanto, Edi, Prayitnaningsih, Seskoati, Wihastuti, Titin Andri, Oktaviono, Yudi Her
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10496361/
https://www.ncbi.nlm.nih.gov/pubmed/37697278
http://dx.doi.org/10.1186/s12872-023-03464-9
_version_ 1785105088836009984
author Suryono, Suryono
Rohman, Mohammad Saifur
Widjajanto, Edi
Prayitnaningsih, Seskoati
Wihastuti, Titin Andri
Oktaviono, Yudi Her
author_facet Suryono, Suryono
Rohman, Mohammad Saifur
Widjajanto, Edi
Prayitnaningsih, Seskoati
Wihastuti, Titin Andri
Oktaviono, Yudi Her
author_sort Suryono, Suryono
collection PubMed
description BACKGROUND: According to WHO 2020, CAD is the second leading cause of death in Indonesia with death cases reaching 259,297 or 15.33% of total deaths. Unfortunately, most of the patients of CAD in Indonesia did not match the golden period or decline to be treated with Percutaneous Coronary Intervention (PCI). Based on the recent study, there were increases in MMP-9, NOX2, and TGF-β1 in STEMI patients which contribute to cardiac remodeling. Moreover, there is controversy regarding the benefit of late PCI (12-48 hours after onset of STEMI) in stable patients. Lately, colchicine is widely used in cardiovascular disease. This study was conducted to explore the effect of colchicine to reduce MMP- 9, NOX2, and TGF-β1 levels after myocardial infarction in stable patients. METHOD: In this clinical trial study, we assessed 129 STEMI patients, about 102 patients who met inclusion criteria were randomized into four groups. Around 25 patients received late PCI (12–48 h after the onset of chest pain), optimal medical treatment (OMT) for STEMI, and colchicine; 24 patients received late PCI and OMT; 22 patients didn’t get the revascularization (No Revas), OMT, and colchicine; and 31 patients received No Revas and OMT only. The laboratory test for MMP-9, NOX2, and TGF-β1 were tested in Day-1 and Day-5. The data were analyzed using Mann-Whitney. RESULTS: A total of 102 patients with mean age of 56 ± 9.9, were assigned into four groups. The data analysis showed significant results within No Revas + OMT + Colchicine group versus No Revas + OMT + Placebo in MMP-9 (Day-1: p = 0.001; Day-5: p = 0.022), NOX2 (Day-1: p = 0.02; Day-5: p = 0.026), and TGF-β1 (Day-1: p = 0.00; Day-5: p = 0.00) with the less three markers in OMT + Colchicine group than OMT + Placebo group. There were no significant differences within the late PCI + OMT + colchicine group and PCI + OMT + Placebo group. CONCLUSIONS: Colchicine could significantly reduce MMP-9, NOX2, and TGF-β1 levels in stable STEMI patients. So that, colchicine could be a potential agent in STEMI patients and prevent cardiac remodeling events.
format Online
Article
Text
id pubmed-10496361
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-104963612023-09-13 Effect of Colchicine in reducing MMP-9, NOX2, and TGF- β1 after myocardial infarction Suryono, Suryono Rohman, Mohammad Saifur Widjajanto, Edi Prayitnaningsih, Seskoati Wihastuti, Titin Andri Oktaviono, Yudi Her BMC Cardiovasc Disord Research BACKGROUND: According to WHO 2020, CAD is the second leading cause of death in Indonesia with death cases reaching 259,297 or 15.33% of total deaths. Unfortunately, most of the patients of CAD in Indonesia did not match the golden period or decline to be treated with Percutaneous Coronary Intervention (PCI). Based on the recent study, there were increases in MMP-9, NOX2, and TGF-β1 in STEMI patients which contribute to cardiac remodeling. Moreover, there is controversy regarding the benefit of late PCI (12-48 hours after onset of STEMI) in stable patients. Lately, colchicine is widely used in cardiovascular disease. This study was conducted to explore the effect of colchicine to reduce MMP- 9, NOX2, and TGF-β1 levels after myocardial infarction in stable patients. METHOD: In this clinical trial study, we assessed 129 STEMI patients, about 102 patients who met inclusion criteria were randomized into four groups. Around 25 patients received late PCI (12–48 h after the onset of chest pain), optimal medical treatment (OMT) for STEMI, and colchicine; 24 patients received late PCI and OMT; 22 patients didn’t get the revascularization (No Revas), OMT, and colchicine; and 31 patients received No Revas and OMT only. The laboratory test for MMP-9, NOX2, and TGF-β1 were tested in Day-1 and Day-5. The data were analyzed using Mann-Whitney. RESULTS: A total of 102 patients with mean age of 56 ± 9.9, were assigned into four groups. The data analysis showed significant results within No Revas + OMT + Colchicine group versus No Revas + OMT + Placebo in MMP-9 (Day-1: p = 0.001; Day-5: p = 0.022), NOX2 (Day-1: p = 0.02; Day-5: p = 0.026), and TGF-β1 (Day-1: p = 0.00; Day-5: p = 0.00) with the less three markers in OMT + Colchicine group than OMT + Placebo group. There were no significant differences within the late PCI + OMT + colchicine group and PCI + OMT + Placebo group. CONCLUSIONS: Colchicine could significantly reduce MMP-9, NOX2, and TGF-β1 levels in stable STEMI patients. So that, colchicine could be a potential agent in STEMI patients and prevent cardiac remodeling events. BioMed Central 2023-09-11 /pmc/articles/PMC10496361/ /pubmed/37697278 http://dx.doi.org/10.1186/s12872-023-03464-9 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Suryono, Suryono
Rohman, Mohammad Saifur
Widjajanto, Edi
Prayitnaningsih, Seskoati
Wihastuti, Titin Andri
Oktaviono, Yudi Her
Effect of Colchicine in reducing MMP-9, NOX2, and TGF- β1 after myocardial infarction
title Effect of Colchicine in reducing MMP-9, NOX2, and TGF- β1 after myocardial infarction
title_full Effect of Colchicine in reducing MMP-9, NOX2, and TGF- β1 after myocardial infarction
title_fullStr Effect of Colchicine in reducing MMP-9, NOX2, and TGF- β1 after myocardial infarction
title_full_unstemmed Effect of Colchicine in reducing MMP-9, NOX2, and TGF- β1 after myocardial infarction
title_short Effect of Colchicine in reducing MMP-9, NOX2, and TGF- β1 after myocardial infarction
title_sort effect of colchicine in reducing mmp-9, nox2, and tgf- β1 after myocardial infarction
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10496361/
https://www.ncbi.nlm.nih.gov/pubmed/37697278
http://dx.doi.org/10.1186/s12872-023-03464-9
work_keys_str_mv AT suryonosuryono effectofcolchicineinreducingmmp9nox2andtgfb1aftermyocardialinfarction
AT rohmanmohammadsaifur effectofcolchicineinreducingmmp9nox2andtgfb1aftermyocardialinfarction
AT widjajantoedi effectofcolchicineinreducingmmp9nox2andtgfb1aftermyocardialinfarction
AT prayitnaningsihseskoati effectofcolchicineinreducingmmp9nox2andtgfb1aftermyocardialinfarction
AT wihastutititinandri effectofcolchicineinreducingmmp9nox2andtgfb1aftermyocardialinfarction
AT oktavionoyudiher effectofcolchicineinreducingmmp9nox2andtgfb1aftermyocardialinfarction